Clinical studies and cases

• Influenza viruses
• Dengue viruses

 

Antiviral Research. 2017 Oct: 3; (147): 142-148.

The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.

Danielle Tilmanis, Carel van Baalen, Ding Yuan Oh, Jean-Francois Rossignol, Aeron C. Hurt 

PLOS Neglected Tropical Diseases. 2013 Aug;7(8):e2203.

Fatal Dengue in Patients with Sickle Cell Disease of Sickle Cell Anemia in Curacao: two case reports.

Fleur M. Moesker, Fred D. Muskiet, Jeanne J. Koeijers, Pieter L. A. Fraaij, Isaac Gerstenbluth, Eric C. M. van Gorp, Albert D. M. E. Osterhaus

  J Infect Dis. 2012 Feb 15;205(4):631-4.

Validation of self-swab for virologic confirmation of influenza virus infections in a community setting.

Ip DK, Schutten M, Fang VJ, Fung RO, Dutkowski RT, Chan KH, Leung GM, Peiris JS, Cowling BJ.

  N Engl J Med. 2010 Sep 30;363(14):1381-2.

Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.

van der Vries E, Stelma FF, Boucher CA.

  N Engl J Med. 2008 Sep 4;359(10):1074-6.

Fatal oseltamivir-resistant influenza virus infection.

van der Vries E, van den Berg B, Schutten M.

  Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1356-61.

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD.

 

Other virusses

HIV Med. 2012 Sep 19.

Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.

Pingen M, van der Ende M, Wensing A, El Barzouhi A, Simen B, Schutten M, Boucher C.

 

Antivir Ther. 2012 Jul 31.

Therapy failure resulting from superinfection by a drug resistant HIV variant.

Pingen M, Nouwen JL, Dinant S, Albert J, Mild M, Brodin J, Simen BB, Walsh S, Kayser M, van der Ende ME, Schutten M, Boucher CA.

  Antivir Ther. 2011;16(5):771-4.

Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-a/ribavirin treatment for chronic hepatitis C.

Roomer R, van Vuuren AJ, Schutten M, Heijens A, Janssen HL, de Knegt RJ.

  PLoS Negl Trop Dis. 2009 Jul 28;3(7):e428.

Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs.

van Thiel PP, de Bie RM, Eftimov F, Tepaske R, Zaaijer HL, van Doornum GJ, Schutten M, Osterhaus AD, Majoie CB, Aronica E, Fehlner-Gardiner C, Wandeler AI, Kager PA.

  J Hosp Infect. 2009 Mar;71(3):199-205. Epub 2009 Jan 14.

Norovirus in a Dutch tertiary care hospital (2002-2007): frequent nosocomial transmission and dominance of GIIb strains in young children.

Beersma MF, Schutten M, Vennema H, Hartwig NG, Mes TH, Osterhaus AD, van Doornum GJ, Koopmans M.

  J Viral Hepat. 2009 Feb;16(2):113-20. Epub 2008 Sep 26.

On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks.

Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, Janssen HL.

  AIDS. 2007 Jul 31;21(12):1661-2.

Complete clinical and virological remission of refractory HIV-related Kaposi’s sarcoma with pegylated interferon alpha.

van der Ende M, Mulder JW, van den Berge M, Blok W, Schutten M.

  N Engl J Med. 2000 Jun 8;342(23):1758-60.

Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2.

Schutten M, van der Ende ME, Osterhaus AD.